Evidence map›Paper›PMID 28899899›Full record

ArticleThe EMBO journal2017

Dual function of UPF3B in early and late translation termination.

Gabriele Neu-Yilik, Etienne Raimondeau, Boris Eliseev, Lahari Yeramala, Beate Amthor, Aurélien Deniaud, Karine Huard, Kathrin Kerschgens, Matthias W Hentze, Christiane Schaffitzel and 1 more

Open access · greenAbstract read
In one paragraph

Article in The EMBO journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

72 citing papers in PubMed, 119 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Functional Activity of Isoform 2 of Human eRF1.International journal of molecular sciences · 2024
    Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Gabriele Neu-YilikDepartment of Pediatric Oncology, Hematology and Immunology, University of Heidelberg, Heidelberg, Germany.
Etienne RaimondeauEuropean Molecular Biology Laboratory, Grenoble, France.
Boris EliseevEuropean Molecular Biology Laboratory, Grenoble, France.
Lahari YeramalaEuropean Molecular Biology Laboratory, Grenoble, France.
Beate AmthorDepartment of Pediatric Oncology, Hematology and Immunology, University of Heidelberg, Heidelberg, Germany.
Aurélien DeniaudEuropean Molecular Biology Laboratory, Grenoble, France.
Karine HuardEuropean Molecular Biology Laboratory, Grenoble, France.
Kathrin KerschgensDepartment of Pediatric Oncology, Hematology and Immunology, University of Heidelberg, Heidelberg, Germany.
Matthias W HentzeMolecular Medicine Partnership Unit, University of Heidelberg and European Molecular Biology Laboratory, Heidelberg, Germany hentze@embl.de christiane.berger-schaffitzel@bristol.ac.uk andreas.kulozik@med.uni-heidelberg.de.
Christiane SchaffitzelEuropean Molecular Biology Laboratory, Grenoble, France hentze@embl.de christiane.berger-schaffitzel@bristol.ac.uk andreas.kulozik@med.uni-heidelberg.de.
Andreas E KulozikDepartment of Pediatric Oncology, Hematology and Immunology, University of Heidelberg, Heidelberg, Germany hentze@embl.de christiane.berger-schaffitzel@bristol.ac.uk andreas.kulozik@med.uni-heidelberg.de.
European Molecular Biology Laboratory · FREuropean Molecular Biology Laboratory · DEHeidelberg University · DENational Center for Tumor Diseases · DE

Funding

European Research Council 281331
6 · The paper itself

Abstract

Nonsense-mediated mRNA decay (NMD) is a cellular surveillance pathway that recognizes and degrades mRNAs with premature termination codons (PTCs). The mechanisms underlying translation termination are key to the understanding of RNA surveillance mechanisms such as NMD and crucial for the development of therapeutic strategies for NMD-related diseases. Here, we have used a fully reconstituted

Indexed as

Peptide Chain Termination, TranslationalCell LineHumansNonsense Mediated mRNA DecayRNA-Binding ProteinsRNA-Binding ProteinsUPF3B protein, humannonsense‐mediated mRNA decaytranslation terminationUPF3B

Identifiers

PMID28899899
PMCPMC5641913
OpenAlexW2755898854

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.